although
investig
initi
focus
himalayan
palm
civet
raccoon
dog
potenti
reservoir
sarscov
infect
multipl
observ
suggest
palm
civet
opportunist
host
rather
primari
reservoir
sarscovlik
virus
wild
marketplac
civet
disproportion
posit
viral
rna
screen
sampl
isol
civet
show
ongo
select
suggest
viru
still
adapt
civet
rather
persist
equilibrium
fact
bioinformat
analysi
suggest
least
three
possibl
transmiss
event
occur
civet
human
first
occur
epidem
indic
presenc
sarscov
antigen
serum
sampl
uninfect
individu
second
occur
main
sar
epidem
third
occur
winter
consist
seri
sporad
addit
molecular
analysi
sampl
taken
healthi
individu
hong
kong
reveal
preval
rate
antibodi
sarsrel
virus
suggest
sarscov
close
ancestor
circul
human
two
group
independ
report
identif
sarscovrel
rna
sequenc
antisar
nucleocapsid
antibodi
rhinolophu
bat
particularli
rhinolophu
sinicu
rhinolophu
interestingli
high
antibodi
titr
correl
low
rna
level
suggest
activ
viral
replic
occur
bat
speci
genom
virus
differ
approxim
epidem
sarscov
suggest
virus
increas
homolog
sarscov
capabl
use
human
bat
orthologu
dock
entri
could
exist
bat
speci
span
famili
estim
bat
order
chiroptera
compris
mammalian
speci
dispers
much
globe
probabl
enhanc
potenti
act
reservoir
pathogen
extrem
virul
potenti
lethal
anim
human
includ
bat
natur
roost
behaviour
combin
ecolog
pressur
select
synanthropi
brought
bat
closer
human
anim
live
proxim
human
probabl
increas
chanc
battoanim
battohuman
fact
scenario
propos
transmiss
sarscovrel
coronavirus
bat
human
bat
roost
near
open
market
sold
civet
china
virus
transmit
civet
via
faecal
andor
oral
shed
human
handl
civet
raw
improperli
cook
civet
meat
thu
complet
transmiss
chain
bat
human
altern
bat
might
directli
transmit
viru
human
via
shed
incident
coinfect
civet
evid
support
hypothesi
genet
reconstruct
r
sinicu
bat
sarscovrel
coronaviru
abl
infect
primat
cell
mous
cell
express
human
molecul
mice
use
model
sarscov
infect
abl
produc
crossneutr
antibodi
sinc
dozen
previous
unknown
bat
coronavirus
identifi
fact
mani
bat
coronavirus
known
distribut
across
coronavirida
famili
enough
evid
suggest
bat
coronavirus
ancestr
sourc
alphacoronaviru
betacoronaviru
fig
addit
recent
studi
report
transmiss
bat
coronaviru
bat
two
differ
subord
support
hypothesi
bat
coinfect
differ
coronavirus
thu
could
enabl
viral
molecular
given
two
new
human
coronavirus
might
emerg
bat
shown
replic
new
world
bat
prioriti
basic
research
global
health
prepared
includ
determin
amount
viru
divers
bat
speci
parallel
map
breadth
bat
coronaviru
host
rang
among
differ
bat
anim
speci
addit
sarscov
evid
human
coronavirus
emerg
bat
includ
newli
emerg
merscov
merscovrel
virus
littl
diverg
merscov
identifi
recent
survey
pipistrellu
bat
captur
ghana
bat
sampl
ghana
also
carri
viral
sequenc
phylogenet
similar
viral
sequenc
sampl
north
american
perimyoti
bat
phylogenet
similar
ref
addit
immort
cell
perimyoti
bat
capabl
host
infect
support
hypothesi
bat
serv
reservoir
also
revers
transmiss
clearli
substanti
evid
broad
array
coronavirus
persist
bat
virus
capac
recombin
emerg
novel
anim
human
pathogen
inde
merscov
close
relat
tylonycteri
bat
coronaviru
pipistrellu
bat
coronaviru
three
virus
probabl
emerg
common
ancestor
sever
centuri
ago
addit
mani
polymorph
detect
spike
protein
sequenc
suggest
viru
extens
bat
coronavirus
capabl
gener
mutant
occupi
new
ecolog
nich
encount
novel
continu
emerg
virul
human
coronavirus
emphas
need
anim
model
studi
viral
replic
pathogenesi
transmiss
thu
far
work
larg
focus
sarscov
infect
sarscov
replic
report
mice
hamster
cat
civet
primat
sever
diseas
symptom
observ
age
anim
merscov
broad
host
rang
provid
promis
develop
small
anim
model
human
diseas
near
futur
howev
function
small
anim
model
merscov
replic
pathogenesi
yet
character
report
possibl
ongo
select
receptorbind
sequenc
spike
protein
sequenc
import
host
specif
might
contribut
limit
inocul
rhesu
macaqu
halfmaxim
tissu
cultur
infecti
dose
merscov
isol
result
transient
mildtomoder
clinic
diseas
includ
local
widespread
howev
lack
small
anim
model
clearli
major
obstacl
further
understand
viral
pathogenesi
test
vaccin
therapeut
sarscov
mous
model
epidem
sarscov
strain
isol
human
encod
receptorbind
domain
rbd
interact
well
human
strain
particularli
sarscov
urbani
capabl
interact
mous
orthologu
replic
mous
lung
small
intestin
diseas
limit
mild
respiratori
symptom
minim
weight
loss
howev
passag
sarscov
urbani
balbc
mice
produc
mouseadapt
variant
sarscov
sarscov
sarscov
caus
sever
lethal
respiratori
diseas
close
resembl
clinic
ill
observ
patient
lead
pneumon
diffus
alveolar
young
mice
adapt
requir
mutat
focus
specif
mutat
site
spike
membran
protein
take
approxim
passag
howev
age
mice
mouseadapt
strain
emerg
within
five
passag
defin
fewer
mutat
occur
variou
locat
across
genom
sarscov
mouseadapt
strain
significantli
pathogen
age
anim
shown
reduct
median
lethal
dose
valu
increas
clinic
diseas
sever
extens
ardsassoci
patholog
lesion
increas
viraemia
rare
transient
mice
common
longlast
subleth
infect
mice
develop
neutral
antibodi
respons
passiv
transfer
sera
mice
protect
recipi
subsequ
lethal
challeng
observ
reflect
probabl
occur
infect
human
epidem
cohort
studi
convalesc
human
sampl
posit
cell
respons
cell
respons
frequent
cell
respons
possess
strongli
neutral
antibodi
cell
epitop
identifi
spike
mous
strain
also
suscept
infect
sarscov
sarscov
mouseadapt
strain
notabl
mice
mice
breadth
suscept
facilit
use
genet
knockout
transgen
anim
relev
transgen
knockout
line
avail
exampl
myeloid
differenti
primari
respons
knockout
signal
transduc
activ
transcript
knockout
anim
defect
innat
immun
develop
sever
diseas
weight
loss
pneumon
bronchiol
die
within
day
infect
anim
death
follow
brief
convalesc
period
resurg
anim
inflammatori
contrast
recombin
activ
gene
rag
knockout
sever
combin
immunodefici
scid
mice
defect
adapt
immun
becom
persist
infect
sarscov
inocul
maintain
viral
titr
least
day
infect
evid
clinic
diseas
cours
entir
infect
probabl
owe
lack
inflammatori
respons
would
normal
occur
result
lymphocyt
sarscov
anim
model
syrian
golden
chines
hamster
also
evalu
model
sarscov
infect
anim
develop
pneumon
inflamm
immun
cell
infiltr
although
sign
clinic
ill
necessarili
accompani
lung
patholog
contrast
mice
hamster
experi
transient
viraemia
becom
less
activ
addit
viru
detect
spleen
liver
although
associ
inflamm
organ
similarli
mice
hamster
also
develop
protect
neutral
antibodi
respons
subsequ
sarscov
challeng
reagent
measur
immun
respons
hamster
improv
still
limit
avail
genet
defin
anim
refin
immunolog
cellular
marker
hamster
model
talenmedi
mutagenesi
mutagenesi
zygot
might
enabl
develop
genet
defin
hamster
atyp
model
speci
pathogenesi
research
ferret
support
sarscov
replic
upper
lower
respiratori
tract
howev
studi
yield
variabl
result
term
sign
infect
multifoc
lesion
develop
lung
surfac
area
detect
gross
patholog
analysi
clinic
symptom
differ
fever
report
sarscovinfect
ferret
addit
nasal
discharg
sneez
viru
shed
ferret
anim
regularli
develop
fever
infect
sarscov
symptom
hallmark
human
ferret
evalu
model
studi
sarscov
transmiss
use
might
provid
interest
inform
genet
basi
superspread
event
observ
epidem
ferret
human
molecul
probabl
requir
differ
mutat
sarscov
rbd
optim
interact
occur
probabl
transmissionevolv
ferretadapt
strain
would
effici
replic
ferret
less
human
howev
studi
might
highlight
residu
region
role
transmiss
alter
host
specif
sarscov
also
serial
passag
young
rat
yield
viru
capabl
enhanc
replic
limit
pathogenesi
young
rat
sever
clinic
diseas
adult
rat
sequenc
analysi
adapt
mutant
show
substitut
spike
vitro
passag
sarscov
chines
hamster
ovari
cho
cell
express
rat
yield
variant
encod
substitut
spike
sequenc
analysi
ratadapt
variant
might
help
identifi
interest
genet
correl
serial
passag
mous
rat
virus
multipl
nonhuman
primat
nhp
suscept
sarscov
infect
includ
rhesu
macaqu
cynomolgu
macaqu
marmoset
african
green
clinic
symptom
patholog
vari
speci
nhp
support
infect
show
evid
sarscov
replic
lung
titr
lung
shed
respiratori
secret
primat
model
develop
histopatholog
chang
show
evid
pneumocyt
infect
degre
diffus
alveolar
damag
diseas
outcom
seem
sever
age
reflect
human
diseas
outcom
human
increas
viru
replic
increas
lung
patholog
note
primat
infect
wildtyp
sarscov
compar
anim
model
except
mice
infect
mouseadapt
sarscov
vaccin
candid
evalu
nhp
probabl
owe
cost
challeng
achiev
statist
signific
sampl
size
nhp
studi
current
approv
antivir
treatment
vaccin
human
coronaviru
infect
includ
sarscov
merscov
studi
describ
smallmolecul
inhibitor
potenti
control
sarscov
infect
vitro
studi
report
viru
partial
ribavirin
interferon
sensit
high
dose
clinic
manag
sever
infect
mostli
occur
peopl
infect
sarscov
merscov
limit
support
palli
thu
develop
safe
stabl
vaccin
necessari
virus
rise
rapidli
heterogen
zoonot
pool
vaccin
would
ideal
broadspectrum
rapidli
adapt
new
coronavirus
particular
import
protect
elderli
might
disproportion
suscept
sever
diseas
sarscov
merscov
infect
support
hypothesi
median
age
mersaffect
patient
experi
diseas
sever
enough
requir
medic
attent
current
year
age
rang
month
year
merscov
incid
updat
addit
case
sarscov
elderli
respond
poorli
vaccin
multipl
strategi
use
gener
coronaviru
vaccin
includ
inactiv
viru
vaccin
liveattenu
viru
vaccin
viral
vector
vaccin
subunit
vaccin
dna
protein
vaccin
studi
focus
sarscov
vaccin
develop
use
anim
model
recapitul
sever
clinic
diseas
occur
human
tabl
critic
evalu
vaccin
lethalchalleng
model
use
viral
strain
homolog
heterolog
vaccin
strain
young
age
anim
essenti
inactiv
viru
vaccin
inactiv
viru
vaccin
use
chemic
formalin
diethylpyrocarbon
radiat
render
viral
genom
noninfecti
maintain
virion
structur
thu
preserv
antigen
elimin
potenti
caus
product
infect
thu
concept
inactiv
viru
vaccin
easili
prepar
antigen
similar
live
viru
sarscov
research
variou
studi
shown
inactiv
vaccin
elicit
product
neutral
administr
inactiv
vaccin
without
adjuv
shown
protect
viral
vaccin
sarscov
challeng
primat
ferret
report
favour
helper
cell
respons
result
product
subsequ
inflammatori
patholog
rather
macrophagedriven
clearanc
observ
typic
antivir
one
particular
inactiv
sarscov
vaccin
doubleinactiv
vaccin
div
use
alum
adjuv
protect
challeng
homolog
viru
howev
induc
eosinophilia
cell
immun
patholog
poor
protect
challeng
heterolog
type
respons
note
inactiv
vector
dna
vaccin
see
respiratori
syncyti
viru
eosinophil
infiltr
associ
increas
mortal
exacerb
lung
eosinophilia
observ
sarscovvaccin
anim
agedepend
might
promot
hypersensit
presenc
inflammatori
respons
enhanc
age
anim
inactiv
sarscov
vaccin
administ
human
vaccin
well
toler
induc
product
neutral
antibodi
although
particip
rel
young
age
rang
year
lung
patholog
assess
addit
absenc
natur
challeng
data
vaccin
efficaci
liveattenu
viru
vaccin
liveattenu
vaccin
produc
reduc
elimin
virul
live
viru
typic
use
chemicaldriven
sitedirect
mutagenesi
thu
viru
capabl
product
infect
result
diseas
either
diminish
elimin
liveattenu
vaccin
elicit
innat
adapt
immun
respons
protect
lifelong
addit
product
develop
revers
genet
coronavirus
particularli
sarscov
greatli
simplifi
investig
attenuationassoci
allel
resist
revers
cell
cultur
mice
evalu
efficaci
attenu
virus
vaccin
candid
envelop
protein
involv
viral
morphogenesi
intracellular
traffick
bud
might
possess
ion
channel
activ
dispens
sarscov
product
howev
replic
attenu
sarscov
lack
sarscov
lack
envelop
protein
initi
construct
wildtyp
rather
mouseadapt
backbon
protect
challeng
partial
protect
mice
transgen
express
human
delet
envelop
protein
engin
backbon
elicit
higher
titr
neutral
antibodi
protect
challeng
age
improv
vaccin
efficaci
probabl
facilit
logincreas
replic
mouseadapt
strain
compar
wildtyp
viru
coronavirus
encod
exonucleas
exon
nonstructur
protein
code
region
exon
shown
mediat
proofread
activ
viral
rnadepend
rna
inactiv
exon
sarscov
yield
viabl
replicationattenu
viru
accumul
mutat
gener
background
sarscov
viru
attenu
growth
pathogenesi
young
age
immunocompromis
mice
fulli
protect
lethal
challeng
elicit
high
level
neutral
antibodi
even
low
vaccin
moreov
sarscov
stabl
term
replic
resist
revers
short
longterm
passag
high
resist
revers
virul
vitro
vivo
might
due
increas
mutat
frequenc
like
continu
introduc
attenu
andor
neutral
mutat
discourag
andor
prohibit
primari
site
origin
mutat
secondari
site
origin
mutat
revers
virul
particular
advantag
approach
involv
conserv
allel
envelop
exon
asid
effect
replic
efficaci
mous
model
test
conserv
allel
make
prime
candid
rapid
gener
new
vaccin
genom
sequenc
novel
emerg
coronaviru
merscov
known
work
focu
stabil
attenu
background
ensur
remain
resist
primari
secondari
revers
virul
recombin
virul
coronavirus
exampl
coronavirus
possess
network
fairli
wellconserv
transcript
regulatori
sequenc
trss
essenti
product
subgenom
mrna
chang
tr
consensu
yield
viabl
virus
reduc
capac
recombin
coronavirus
method
show
great
promis
render
vaccin
candid
refractori
recombin
natur
occur
virul
coronavirus
enhanc
safeti
use
genet
engin
coronavirus
live
recent
develop
merscov
revers
genet
system
approach
also
test
newest
emerg
vaccin
approach
viralvector
vaccin
function
viral
gene
deliveri
system
reli
host
viral
genom
exampl
adenoviru
typic
lack
genet
compon
necessari
produc
new
virion
encod
antigen
compon
viru
interest
elicit
immun
respons
viralvector
vaccin
persist
host
genet
materi
directli
infect
antigenpres
cell
strong
inher
adjuv
activ
effici
induc
innat
b
cell
cellmedi
immun
respons
adenoviru
vector
express
sarscov
spike
nucleocapsid
protein
immunodomin
coronaviru
protein
yield
vari
result
depend
prepar
rout
administr
anim
model
use
howev
challeng
experi
alway
although
intramuscular
vaccin
induc
high
serum
titr
neutral
antibodi
intranas
inocul
effect
prevent
replic
challeng
viru
suggest
intranas
rout
effici
induc
mucos
sidebysid
comparison
inactiv
viru
adenovirusvector
vaccin
produc
significantli
lower
titr
neutral
antibodi
protect
subsequ
challeng
although
protect
inactiv
viru
venezuelan
equin
enceph
viru
vee
viral
replicon
particl
vrp
also
use
express
sarscov
spike
nucleocapsid
protein
spikeexpress
vrp
vrp
vaccin
protect
lethal
homolog
challeng
young
age
balbc
mice
challeng
lethal
viru
express
heterolog
spike
protein
young
mice
protect
short
viral
vector
use
spike
protein
includ
parainfluenza
rabi
vesicular
stomat
confirm
product
neutral
antibodi
demonstr
protect
convers
vaccin
vrp
construct
express
sarscov
nucleocapsid
protein
result
cellskew
immun
respons
immun
patholog
lung
protect
homolog
heterolog
similarli
vector
vaccin
subunit
vaccin
util
antigen
compon
viru
interest
contrast
vector
vaccin
propag
organ
grown
laboratori
rather
vaccine
antigen
compon
harvest
use
vaccin
sarscov
subunit
vaccin
contain
either
spike
protein
fragment
consist
amino
acid
nucleocapsid
protein
crystal
structur
sarscov
merscov
spike
protein
rbd
solv
complex
correspond
receptor
interact
residu
map
domain
obviou
target
subunit
vaccin
addit
subunit
spike
vaccin
produc
higher
neutral
antibodi
titr
liveattenu
sarscov
poxviru
spike
protein
dna
spike
protein
dna
subunit
nucleocapsid
vaccin
induc
high
level
b
cell
cellmedi
immun
respons
howev
vivo
challeng
experi
yet
dna
vaccin
consist
dna
encod
viral
antigen
compon
directli
inject
otherwis
inocul
vaccine
vector
subunit
vaccin
dna
vaccin
also
use
spike
peptid
elicit
high
titr
neutral
interestingli
dna
vaccin
use
combin
inactiv
vaccin
cellular
immun
respons
celldirect
wherea
vaccin
inactiv
viru
alon
induc
cell
respons
similarli
viral
nucleocapsid
protein
vector
vaccin
dna
vaccin
encod
nucleocapsid
protein
induc
strong
cellmedi
immun
protect
hightitr
challeng
addit
unlik
spike
protein
vaccin
dnanucleocapsid
dnan
vaccin
induc
delayedtyp
hypersensit
even
absenc
antibodi
importantli
subunit
dna
vaccin
rigor
test
either
young
age
anim
lethalchalleng
model
true
vivo
efficaci
current
unknown
emerg
sarscov
taught
us
mani
lesson
zoonot
reservoir
import
identifi
anim
model
recapitul
variou
aspect
human
diseas
determin
vaccin
efficaci
safeti
knowledg
appli
recent
emerg
merscov
human
popul
strikingli
high
morbid
mortal
rate
hospit
individu
clear
merscov
potenti
profound
impact
human
popul
howev
low
penetr
thu
far
suggest
viru
might
ultim
fail
develop
nich
human
might
still
adapt
human
host
worst
effect
yet
come
studi
sarscov
suggest
merscov
research
focu
establish
anim
model
recapitul
replic
pathogenesi
transmiss
human
prioriti
develop
treatment
prevent
viralinduc
immun
patholog
particularli
elderli
furthermor
vaccin
target
conserv
allel
provid
broad
protect
strain
close
distantli
relat
vaccin
strain
develop
one
particular
concern
possibl
merscov
vaccin
elicit
cell
immun
patholog
seen
inactiv
vector
dna
sarscov
vaccin
liveattenu
vaccin
vaccin
combin
exampl
inactiv
viru
combin
dna
vaccin
seem
induc
immun
phenomenon
thu
approach
might
hold
promis
develop
success
vaccin
strategi
particularli
older
popul
adjuv
promot
robust
cell
respons
also
evalu
rigor
model
second
concern
sarscov
escap
neutral
driven
spike
protein
variabl
thu
spikedepend
vaccin
strategi
might
requir
multival
merscov
natur
variat
merscov
spike
glycoprotein
mostli
unknown
thu
essenti
natur
isol
recov
sequenc
human
reservoir
speci
focus
prioriti
help
combat
emerg
merscov
also
increas
prepared
futur
coronaviru
emerg
event
origin
vast
mutabl
zoonot
reservoir
heterolog
sarscov
merscovrel
isol
encod
even
minut
variat
spike
protein
import
reagent
evalu
vaccin
efficaci
futur
emerg
strain
coronaviru
phylogeni
demonstr
incred
divers
antigen
variant
lead
limit
crossprotect
infect
differ
strain
even
within
phylogenet
subclust
consequ
risk
introduc
novel
coronavirus
naiv
human
anim
popul
remain
high
despit
antigen
breadth
reveal
alphacoronavirus
betacoronavirus
often
use
receptor
orthologu
andor
recogn
carbohydr
crossspeci
transmiss
given
larg
number
bat
speci
ecolog
enabl
potenti
pathogen
spread
bat
popul
number
bat
coronavirus
might
natur
abl
recogn
human
orthologu
receptor
dock
entri
recent
studi
analys
viral
biodivers
fli
fox
pteropu
giganteu
support
hypothesi
coronaviru
speci
among
sever
potenti
novel
viral
speci
identifi
pcr
moreov
phylogeni
cornonavirus
appear
human
popul
indic
acceler
pattern
emerg
diseas
outbreak
zoonot
sourc
molecular
clock
analys
estim
date
emerg
year
ago
year
ago
year
ago
pedv
year
ago
respiratori
bovin
cov
rbcov
year
ago
sarscov
year
ago
merscov
year
ago
fig
demonstr
potenti
paradigm
shift
relationship
coronavirus
domest
anim
human
host
bat
coronavirus
probabl
evolv
transmit
close
proxim
broader
host
tropism
result
larg
multispeci
bat
popul
exist
across
much
globe
pattern
transmiss
facilit
spread
coronavirus
host
exampl
intens
farmmanag
practic
result
thousand
anim
hous
togeth
close
environ
human
popul
densiti
increas
past
year
encroach
wild
anim
habitat
addit
averag
age
human
popul
increas
proport
immunocompromis
individu
suscept
sever
lung
infect
condit
provid
vulner
host
sever
diseas
anim
model
repres
process
human
lead
rapid
vivo
evolut
virul
transmiss
fig
fact
earli
case
sarscov
merscov
describ
elderli
aros
close
contact
hospit
famili
emerg
virul
sarscov
background
older
host
could
requir
fewer
mutat
less
passag
requir
young
moreov
close
proxim
import
determin
effici
coronaviru
crossspeci
transmiss
dissemin
possibl
current
project
ecolog
demograph
condit
approach
critic
point
coronavirida
famili
pois
excel
condit
colon
grow
nich
hypothes
correct
acceler
transmiss
bat
anim
coronavirus
human
expect
continu
possibl
escal
public
health
author
prepar
develop
broadli
applic
platform
strategi
rapid
diagnosi
contain
treatment
vaccin
emerg
coronaviru
infect
warn
twice
recent
year
belief
coronavirus
highli
vulner
public
health
intervent
strategi
support
increas
incid
coronaviru
emerg
livestock
anim
popul
identif
novel
coronavirus
reservoir
speci
despit
applic
widespread
diseas
manag
practic
intervent
strategi
recent
identif
bat
sarslik
coronavirus
chines
horsesho
bat
capabl
use
bat
human
receptor
strongli
support
argument
sarscov
emerg
human
infect
directli
bat
reservoir
data
emphas
import
survey
synanthrop
wildlif
popul
potenti
zoonot
candid
